In order to curb the rapid dissemination of the B.1.351 variant of SARS-CoV-2 in the district of Schwaz and beyond, the EU allocated additional vaccine doses at the beginning of March 2021 to implemen
Seroprevalence of Canadians aged 1 and older with antibodies against SARS-CoV-2 (the virus that causes COVID-19), overall and by antibody type, by age group and sex.
